Compare Goldman Sachs Physical Gold ETF (AAAU) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs Incyte Corporation — how do they compare? Goldman Sachs Physical Gold ETF trades at $40.18, while Incyte Corporation trades at $117.33 (market cap $23.10B). The key difference: Incyte Corporation is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.
| AAAU | INCY | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $118.05 |
52-Week Low | $32.29 | $67.38 |
Market Cap | — | $23.10B |
Enterprise Value | — | $19.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused investment vehicle, trades at $41.04 with a 1.01% daily gain. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The stock faces resistance at $41 with support at $40. Recent gold market dynamics show central bank accumulation and analyst price targets ranging from $4,500-$5,500 per ounce for the underlying commodity.
Gold's structural tailwinds from central bank demand and inflation hedging support long-term upside, though near-term headwinds include Fed policy uncertainty and dollar strength. The stock offers exposure to gold's safe-haven appeal but remains vulnerable to interest rate volatility and technical resistance levels.
Incyte (INCY) trades at $118.05, up 1.02% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion and a robust net margin of 26.71%. Recent catalysts include the acquisition of Vega Therapeutics and positive regulatory updates for Opzelura in Europe, supporting momentum.
The outlook remains positive given earnings beats, expanding product portfolio, and analyst consensus leaning buy. Key risks include reliance on key drugs, regulatory hurdles, and competitive pressures. The stock trades above the consensus price target of $109.14, suggesting near-term consolidation potential amid overbought RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
